Luteolin prevents monoiodoacetate-induced osteoarthritis in post-menopausal rats via protection of the cartilage

Résumé

Purpose: To investigate the effectiveness of luteolin treatment in postmenopausal model of osteoarthritis (OA)Methods: Sprague-Dawley rats were divided into five groups. Luteolin was given orally to rats at doses of 50 and 100 mg/kg for 4 months, while aceclofenac was administered at a dose of 10 mg/kg. The antiinflammatory and anti-arthritic effects of luteolin and aceclofenac were determined using paw-withdrawal method. Knee joint thickness was measured using X-ray imaging. Pathological changes in bone slices were determined with immuno-histochemical evaluation. The levels of inflammatory cytokines were assessed by reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis.Results: Oral ingestion of luteolin significantly reduced manifestations of OA and suppressed levels of serum cytokines (p < 0.05). Moreover, luteolin increased expression of bone marker protein and reduced the gene expression levels of matrix metalloproteinases (MMPs, p < 0.05), suggesting its protective effects on chondrocytes. Luteolin significantly reduced the production of inflammatory chemokines and cytokines (IFN-γ, IL-1, and IL-6). Histopathological examination showed that luteolindecreased pathological lesions in monoiodoacetate-mediated OA in ovariectomized rats, indicatingprevention of cartilage loss.Conclusion: These results suggest that luteolin exerts protective effects against monoiodoacetateinduced (MIA) OA in ovariectomized rats by suppressing the expressions of inflammation-related mediators (IL-1β, Cox-2, and PGE-2). Thus, luteolin is a prospective option for the suppression of postmenopausal OA in humans.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0